Radiation boosts immunotherapy in kidney cancer trial

NCT ID NCT04090710

Ongoing Disease control Sponsor: Ontario Clinical Oncology Group (OCOG) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether adding precise, high-dose radiation (SBRT) to standard immunotherapy (ipilimumab and nivolumab) can help people with metastatic kidney cancer live longer without their disease getting worse. About 66 participants with intermediate or poor-risk disease will either get immunotherapy alone or immunotherapy plus radiation to their primary kidney tumor. The study is active but no longer recruiting, and results are expected to show if the combination improves progression-free survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ipilimumab (Yervoy) and Nivolumab (Opdivo) with or without stereotactic body radiation therapy (SBRT)
What this could lead to: If it works, this could show that adding targeted radiation to immunotherapy helps control metastatic kidney cancer longer than immunotherapy alone.
What could go wrong: This is a mid-stage trial with only 66 participants, so results may not apply to everyone. Adding radiation may increase side effects without improving outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC RENAL CELL CARCINOMA

Contacts and locations

Locations

Cross Cancer Institute

Edmonton, Alberta, T6G 1Z2, Canada
Grand River Regional Cancer Centre

Kitchener, Ontario, N2G1G3, Canada
Juravinski Cancer Centre

Hamilton, Ontario, Canada
London Regional Cancer Centre

London, Ontario, N2G1G3, Canada
Peter MacCallum Cancer Centre

Melbourne, 3000, Australia
Sunnybrook Health Sciences Centre- Odette Cancer Centre

Toronto, Ontario, M4N3M5, Canada
The Ottawa Regional Cancer Centre

Ottawa, Ontario, K1H8L6, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.